Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Journal of Cancer

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2017.10.014PMID 29149761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

  2017influential reference
• Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

  2016influential reference
• First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

  2015cited by this paper
• Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity.

  2015cited by this paper
• Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy

  2014cited by this paper
• MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array

  2014cited by this paper
• Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes

  2014cited by this paper
• Predicting resistance by selection of signaling pathways.

  2014cited by this paper
• EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer

  2014cited by this paper
• Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

  2014cited by this paper
• Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology.

  2014cited by this paper
• Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

  2013cited by this paper
• MET: a promising anticancer therapeutic target

  2012cited by this paper
• A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.

  2012cited by this paper
• Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.

  2012cited by this paper
• An overview of the c-MET signaling pathway

  2011cited by this paper
• Familial Renal Cancer: Molecular Genetics and Surgical Management

  2011cited by this paper
• Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

  2010cited by this paper
• Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

  2009cited by this paper
• Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

  2009cited by this paper
• Guidelines on Renal Cell Carcinoma

  2007cited by this paper
• Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics

  2007cited by this paper
• 2004 WHO classification of the renal tumors of the adults.

  2006cited by this paper
• A molecular classification of papillary renal cell carcinoma.

  2005cited by this paper
• Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality.

  2003cited by this paper
• Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma.

  2002cited by this paper
• Novel mutations of the MET proto-oncogene in papillary renal carcinomas

  1999cited by this paper
• Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors.

  1997cited by this paper
• Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

  1997cited by this paper
• Papillary renal tumors. Morphologic, cytochemical, and genotypic features

  1995cited by this paper

• Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas

  2025cites this paper
• Genomic profiling of urological malignancies using tissue-based next generation sequencing.

  2025cites this paper
• Systemic therapy for non–clear cell renal cell carcinomas: A systematic review

  2024cites this paper
• The MET Oncogene: An Update on Targeting Strategies

  2024cites this paper
• Papillary Renal Cell Carcinoma: Current Evidence and Future Directions

  2024influential citation
• Recording and classifying MET receptor mutations in cancers

  2024cites this paper
• New clinical trial design in precision medicine: discovery, development and direction

  2024cites this paper
• The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma

  2024cites this paper
• Hereditary Renal Cancer Syndromes

  2024cites this paper
• Monitoring phosphorylation and acetylation of CRISPR-mediated HiBiT-tagged endogenous proteins

  2024cites this paper
• Molecularly Defined Renal Carcinomas

  2024cites this paper
• Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective

  2024cites this paper
• Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

  2023cites this paper
• Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

  2023cites this paper
• Mesenchymal–Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis

  2023cites this paper
• A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma

  2023cites this paper
• Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy

  2023cites this paper
• An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases

  2023cites this paper
• Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience

  2023cites this paper
• MET Inhibitors for Papillary Renal Cell Carcinoma

  2023cites this paper
• Renal Cell Carcinoma of Variant Histology: Biology and Therapies.

  2023cites this paper
• Identification of Five Tumor Antigens for Development and Two Immune Subtypes for Personalized Medicine of mRNA Vaccines in Papillary Renal Cell Carcinoma

  2023cites this paper
• Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature

  2023cites this paper
• "Rare cancers": not all together in clinical studies!

  2022cites this paper
• Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer

  2022cites this paper
• Tumorigenesis Mechanisms Found in Hereditary Renal Cell Carcinoma: A Review

  2022cites this paper
• Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy

  2022cites this paper
• Bioinformatically-expanded next-generation sequencing analysis optimizes identification of therapeutically relevant MET copy number alterations in >50,000 tumors.

  2022cites this paper
• Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines

  2022cites this paper
• Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma

  2022cites this paper
• Advanced nccRCC: what therapeutic options in 2022?

  2022cites this paper
• Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment

  2022cites this paper
• Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data.

  2022cites this paper
• Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review

  2022cites this paper
• Comprehensive Analysis of Pyroptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Papillary Renal Cell Carcinoma

  2022cites this paper
• MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review

  2022influential citation
• Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma

  2022influential citation
• Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?

  2022cites this paper
• Survival Outcomes of Patients in Advanced Non-Clear Renal Cell Carcinoma Treated with Pazopanib: A Retrospective Single Institution Experience

  2021cites this paper
• Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer.

  2021cites this paper
• Anti‐tumor efficacy of human anti‐c‐met CAR‐T cells against papillary renal cell carcinoma in an orthotopic model

  2021cites this paper
• A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.

  2021cites this paper
• Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies

  2021cites this paper
• A challenging frontier – the genomics and therapeutics of nonclear cell renal cell carcinoma

  2021cites this paper
• Are tyrosine kinase inhibitors fit for purpose in the treatment of metastatic papillary renal cell carcinoma?

  2021cites this paper
• ZALECENIA POSTĘPOWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO W RAKU NERKOWOKOMÓRKOWYM

  2021cites this paper
• Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.

  2021cites this paper
• Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.

  2021cites this paper
• Papillary renal cell carcinoma: Review.

  2021cites this paper
• ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?

  2021cites this paper
• The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?

  2021cites this paper
• Kidney cancer: from genes to therapy.

  2021cites this paper
• Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Novel Prognostic Immunohistochemical Markers in Uveal Melanoma-Literature Review

  2021cites this paper
• Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views

  2021influential citation
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

  2021cites this paper
• Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren

  2021cites this paper
• GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT Polish Society of Clinical Oncology and Polish Urological Association Guidelines for the diagnosis and treatment of renal cell cancer

  2021cites this paper
• Cabozantinib: a new first-line option for papillary renal cell carcinoma?

  2021cites this paper
• Anaplastic lymphoma kinase (ALK) rearrangement in adult renal cell carcinoma with lung metastasis: a case report and literature review

  2020cites this paper
• Management of Metastatic Nonclear-Clear Cell Renal Cell Carcinoma: What Are the Oare the options and Challenges?

  2020cites this paper
• Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma

  2020cites this paper
• [Non-clear cell renal cell carcinoma: clinico-biological characteristics and therapeutic management except surgery].

  2020cites this paper
• Basket trials: From tumour gnostic to tumour agnostic drug development.

  2020cites this paper
• Spectrum of Mesenchymal–Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis

  2020cites this paper
• Targetable gene fusions and aberrations in genitourinary oncology

  2020cites this paper
• Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

  2020cites this paper
• MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features

  2020cites this paper
• Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.

  2020cites this paper
• Genomic profiling in renal cell carcinoma

  2020cites this paper
• Current perspectives on systemic therapy for metastatic non-clear cell renal cell carcinoma

  2020cites this paper
• Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.

  2020cites this paper
• The genetic landscapes of urological cancers and their clinical implications in the era of high‐throughput genome analysis

  2020cites this paper
• MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.

  2020cites this paper
• Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.

  2020cites this paper
• Tropomyosin receptor kinase inhibitors in the management of sarcomas.

  2020cites this paper
• Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma

  2020cites this paper
• Tropomyosin receptor kinase inhibitors in the management of sarcomas.

  2020cites this paper
• Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma.

  2020cites this paper
• A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma

  2020cites this paper
• Management of Metastatic Renal Cell Carcinoma with Variant Histologies.

  2020cites this paper
• Mutations in renal cell carcinoma.

  2020cites this paper
• Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.

  2020cites this paper
• Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.

  2020cites this paper
• Oncology in the Precision Medicine Era: Value-Based Medicine

  2020influential citation
• Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas

  2019cites this paper
• New entities, new technologies, new findings: A review of the cytologic features of recently established subtypes of renal cell carcinoma

  2019cites this paper
• Safety and Tolerability of c-MET Inhibitors in Cancer

  2019cites this paper
• A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial.

  2019cites this paper
• Renal Cell Carcinoma

  2019cites this paper
• Implementing precision cancer medicine in the genomic era.

  2019cites this paper
• Cytology of Kidney Tumors

  2019cites this paper
• MET inhibitors in cancer: pitfalls and challenges

  2019influential citation
• Basket Designs: Statistical Considerations for Oncology Trials.

  2019cites this paper
• Investigational MET inhibitors to treat Renal cell carcinoma

  2019cites this paper
• Treatment selection in metastatic renal cell carcinoma : Towards an individualised approach

  2019cites this paper
• Personalisierte Medizin bei Nierenzelltumoren

  2019cites this paper
• Emerging therapeutic agents for genitourinary cancers

  2019cites this paper
• The role of MET in melanoma and melanocytic lesions.

  2019cites this paper
• A Review of Papillary Renal Cell Carcinoma and MET Inhibitors

  2019cites this paper